Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

<p>Announced initial clinical data from dose-escalation portion of Phase 1 clinical trial of BDTX-1535, an EGFR MasterKey inhibitor, demonstrating a favorable tolerability profile and clinical proof of activity based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patients harboring acquired resistance and intrinsic driver EGFR mutations Initiated BDTX-1535 NSCLC expansion cohorts in […]</p>
<p>The post <a rel="nofollow" href="https://forextv.com/top-news/black-diamond-therapeutics-reports-second-quarter-2023-financial-results-and-provides-corporate-update/">Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update</a> appeared first on <a rel="nofollow" href="https://forextv.com">ForexTV</a>.</p>